Mechanism of GABA receptor-mediated inhibition of spontaneous GABA release onto cerebellar Purkinje cells

Eur J Neurosci. 2004 Aug;20(3):684-700. doi: 10.1111/j.1460-9568.2004.03505.x.

Abstract

gamma-Aminobutyric acid (GABA)(B) receptor-mediated modulation of spontaneous GABA release onto Purkinje cells was investigated in cerebellar slices from 3- to 5-week-old mice. The GABA(B) receptor agonists baclofen and CGP 44533 each reduced the frequency of miniature inhibitory postsynaptic currents (mIPSCs), with no significant effect on mIPSC amplitude; together, consistent with a presynaptic site of action. The GABA(B) receptor antagonist CGP 55845 blocked baclofen-induced inhibition. The sulphydryl alkylating agent N-ethylmaleimide occluded baclofen effects, implicating G(i/o) subunits in mediating a GABA(B) G protein-coupled receptor pathway. Baclofen-induced inhibition persisted in the presence of Ba(2+), a blocker of K(+) channels, and Cd(2+), a blocker of Ca(2+) channel-mediated GABA release. Application of nominally Ca(2+)-free extracellular solutions reduced mIPSC frequency and amplitude; however, baclofen produced a significant inhibition in mIPSC frequency, further suggesting that this pathway was independent of Ca(2+) influx. Spontaneous GABA release was increased by the adenylate cyclase activator, forskolin, and the phorbol ester, phorbol 12,13-dibutyrate. However, baclofen-induced inhibition was not significantly changed in either condition. Baclofen action was also not affected by the adenylate cyclase inhibitor SQ 22536 or the protein kinase C inhibitor chelerythrine chloride. Baclofen still reduced mIPSC frequency in the presence of the polyvalent cation ruthenium red, which acts as a secretagogue here; however, baclofen-induced inhibition was reduced significantly. Furthermore, baclofen produced no clear inhibition during high-frequency mIPSCs bursts induced by the potent secretagogue alpha-Latrotoxin. Together, these results suggest that GABA(B) inhibition occurs downstream of Ca(2+) influx and may be mediated, in part, by an inhibition of the vesicular release mechanism.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Age Factors
  • Animals
  • Baclofen / pharmacology
  • Barium / pharmacology
  • Cadmium / pharmacology
  • Calcium / metabolism
  • Cerebellum / cytology*
  • Cerebellum / drug effects
  • Colforsin / pharmacology
  • Drug Interactions
  • Enzyme Inhibitors / pharmacology
  • Exotoxins / pharmacology
  • GABA Agonists / pharmacology
  • GABA Antagonists / pharmacology
  • In Vitro Techniques
  • Male
  • Mice
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology*
  • Patch-Clamp Techniques / methods
  • Phosphinic Acids / pharmacology
  • Propanolamines / pharmacology
  • Purkinje Cells / drug effects
  • Purkinje Cells / metabolism*
  • Receptors, GABA-A / physiology*
  • Ruthenium Red / pharmacology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Tetrodotoxin / antagonists & inhibitors
  • Tetrodotoxin / pharmacology
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Enzyme Inhibitors
  • Exotoxins
  • GABA Agonists
  • GABA Antagonists
  • Phosphinic Acids
  • Propanolamines
  • Receptors, GABA-A
  • leukotoxin
  • Cadmium
  • Ruthenium Red
  • CGP 55845A
  • Colforsin
  • Barium
  • Tetrodotoxin
  • gamma-Aminobutyric Acid
  • Baclofen
  • Calcium